|
KR20210005950A
|
|
Selection of patients for combination therapy
|
|
CN111278459A
|
|
Combination therapy
|
|
WO2018183366A1
|
|
Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
|
|
CN108430472A
|
|
Combination for the hdac inhibitor and anti-PD-L1 antibody for the treatment of oophoroma
|
|
KR20180048703A
|
|
Selection of patients for combination therapy
|
|
CN107921108A
|
|
Combination for the hdac inhibitor and anti-PD L1 antibody for the treatment of cancer
|
|
CA2980297A1
|
|
Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer
|
|
KR20160003182A
|
|
Methods for the treatment of cancer
|
|
US2013150386A1
|
|
Methods for the treatment of lung cancer
|
|
WO2013033656A1
|
|
Methods for the treatment of breast cancer
|
|
WO2012166645A1
|
|
Prodrugs of azacitidine 5' -diphosphate
|
|
WO2011153374A1
|
|
Prodrugs of azacitidine 5'-phosphate
|
|
CA2725390A1
|
|
Use of a hdac inhibitor and a her-2 inhibitor in the treatment of breast cancer
|
|
WO2009126537A1
|
|
Administration of an inhibitor of hdac and an hmt inhibitor
|
|
WO2009067500A1
|
|
Administration of an inhibitor of hdac
|
|
WO2009067453A1
|
|
Combinations of hdac inhibitors and proteasome inhibitors
|
|
WO2009058895A1
|
|
Administration of an inhibitor of hdac and an mtor inhibitor
|
|
WO2009049018A1
|
|
Novel compounds and methods of using them
|
|
WO2009015237A1
|
|
Novel compounds and methods of using them
|
|
WO2009015179A1
|
|
Novel compounds and methods of using them
|
